Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis

Adequate concentrations of beta-lactam antibiotics in cerebrospinal fluid (CSF) are difficult to achieve for meningitis caused by drug-resistant Streptococcus pneumoniae. Ceftriaxone in dosages of 150 or 400 mg/kg of body weight per day, given in one or two doses, was used for the treatment of experimental highly cephalosporin-resistant (MIC and MBC, 4 microg/ml) pneumococcal meningitis. The bacterial killing rate (delta log10 CFU per milliliter per hour) and pharmacokinetic indices, including percentage of time the antibiotic concentration exceeded the MBC during a 24-h period (T>MBC), CSF peak concentration above the MBC, and area under the concentration-time curve from 0 to 24 h above MBC, were measured and correlated. By multiple stepwise regression, only T>MBC independently predicted the bacterial killing rate. There was a direct linear correlation between T>MBC in CSF and the bacterial killing rate during the first 24 h of therapy (r = 0.87; P = 0.004). Sterilization of CSF was achieved only when the T>MBC was 95 to 100%. In the first 24 h, the 200-mg/kg/12-h regimen, compared with the 400-mg/kg/24-h regimen, was associated with a greater T>MBC (87% +/- 10% versus 60% +/- 22%; P = 0.03) and greater bacterial killing rate (0.2 +/- 0.04 versus 0.13 +/- 0.07; P = 0.003), confirming that ceftriaxone exhibits time-dependent bactericidal activity. After 24 h, the T>MBC and the CSF sterilization rates were similar whether ceftriaxone was given once or twice daily.

[1]  J. Bédos,et al.  Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains , 1996, Antimicrobial agents and chemotherapy.

[2]  C. Cabellos,et al.  High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins , 1996, Antimicrobial agents and chemotherapy.

[3]  O. Ramilo,et al.  Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae , 1995, Antimicrobial agents and chemotherapy.

[4]  N. Frimodt-Møller,et al.  Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin , 1995, Antimicrobial agents and chemotherapy.

[5]  W. Craig Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. , 1995, Diagnostic microbiology and infectious disease.

[6]  J. Pocidalo,et al.  In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model , 1994, Antimicrobial Agents and Chemotherapy.

[7]  G. Mccracken,et al.  Time-kill studies of antibiotic combinations against penicillin-resistant and -susceptible Streptococcus pneumoniae. , 1994, The Journal of antimicrobial chemotherapy.

[8]  S. Kaplan,et al.  Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins , 1994, Antimicrobial Agents and Chemotherapy.

[9]  J. B. D. Bernaldo de Quirós,et al.  Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  G. Mccracken,et al.  Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. , 1993, The Pediatric infectious disease journal.

[11]  Jerome J. Schentag,et al.  Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin , 1991, DICP : the annals of pharmacotherapy.

[12]  W. Jusko,et al.  Ion-paired reversed-phase high-performance liquid chromatography assay for determination of ceftriaxone in human plasma and urine. , 1989, Journal of pharmaceutical sciences.

[13]  S. Kunz,et al.  Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits , 1989, Antimicrobial Agents and Chemotherapy.

[14]  W. Craig,et al.  Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. , 1989, The Journal of infectious diseases.

[15]  J. Turnidge,et al.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.

[16]  A. Tomasz,et al.  Penicillin resistance and defective lysis in clinical isolates of pneumococci: evidence for two kinds of antibiotic pressure operating in the clinical environment. , 1988, The Journal of infectious diseases.

[17]  A. Tomasz,et al.  Penicillin tolerance in multiply drug-resistant natural isolates of Streptococcus pneumoniae. , 1985, The Journal of infectious diseases.

[18]  M. Sande,et al.  The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits. , 1984, The Journal of infectious diseases.

[19]  T. Drake,et al.  Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. , 1984, The Journal of infectious diseases.

[20]  J. Ernst,et al.  Correlation of in vitro time-kill curves and kinetics of bacterial killing in cerebrospinal fluid during ceftriaxone therapy of experimental Escherichia coli meningitis , 1983, Antimicrobial Agents and Chemotherapy.

[21]  M. Sande,et al.  Effect of Probenecid on Cerebrospinal Fluid Concentrations of Penicillin and Cephalosporin Derivatives , 1974, Antimicrobial Agents and Chemotherapy.

[22]  W. Craig,et al.  Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. , 1993, The Journal of antimicrobial chemotherapy.